{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT03391466_ZUMA7\\NCT03391466_ZUMA7_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set (FAS) includes all subjects randomized to the study. Subjects will be analyzed according to the treatment group to which they were randomized.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The Full Analysis Set (FAS) includes all subjects randomized to the study. Subjects will be analyzed according to the treatment group to which they were randomized.",
        "criteria": "All randomized subjects"
      },
      {
        "id": "pop_2",
        "name": "Safety Analysis Set",
        "text": "The Safety Analysis Set includes all subjects who received at least one dose of study treatment (axicabtagene ciloleucel or SOC). Subjects will be analyzed according to the treatment they actually received.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The Safety Analysis Set includes all subjects who received at least one dose of study treatment (axicabtagene ciloleucel or SOC). Subjects will be analyzed according to the treatment they actually received.",
        "criteria": "Received at least one dose of study treatment"
      },
      {
        "id": "pop_3",
        "name": "Safety Analysis Set - ASCT",
        "text": "The Safety Analysis Set - ASCT includes all subjects in the SOC arm who received high-dose therapy (HDT) and autologous stem cell transplant (ASCT).",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF-ASCT",
        "populationDescription": "The Safety Analysis Set - ASCT includes all subjects in the SOC arm who received high-dose therapy (HDT) and autologous stem cell transplant (ASCT).",
        "criteria": "Randomized to SOC arm AND received HDT and ASCT"
      },
      {
        "id": "pop_4",
        "name": "QoL Analysis Set",
        "text": "The QoL Analysis Set includes all subjects in the FAS who have a baseline and at least one post-baseline QoL assessment.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "QoL Set",
        "populationDescription": "The QoL Analysis Set includes all subjects in the FAS who have a baseline and at least one post-baseline QoL assessment.",
        "criteria": "Randomized AND has baseline QoL assessment AND has >=1 post-baseline QoL assessment"
      },
      {
        "id": "pop_5",
        "name": "Retreatment Analysis Sets",
        "text": "The Retreatment Analysis Sets include all subjects who receive a second course of axicabtagene ciloleucel treatment.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Retreatment Set",
        "populationDescription": "The Retreatment Analysis Sets include all subjects who receive a second course of axicabtagene ciloleucel treatment.",
        "criteria": "Received second course of axicabtagene ciloleucel"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age at randomization",
        "code": "AGE_AT_RANDOMIZATION",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age at randomization",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Age categorized as ≥ 65 or < 65 years"
      },
      {
        "id": "char_2",
        "name": "Response to first-line therapy",
        "code": "RESPONSE_TO_FIRST-LI",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Response to first-line therapy",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Primary refractory versus relapse ≤ 6 months versus relapse > 6 and ≤ 12 months"
      },
      {
        "id": "char_3",
        "name": "Second-line age-adjusted IPI",
        "code": "SECOND-LINE_AGE-ADJU",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Second-line age-adjusted IPI",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "International Prognostic Index (0 to 1 versus 2 to 3) at time of screening"
      },
      {
        "id": "char_4",
        "name": "ECOG performance status",
        "code": "ECOG_PERFORMANCE_STA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "ECOG performance status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Performance status at screening (0, 1)"
      }
    ],
    "summary": {
      "populationCount": 5,
      "characteristicCount": 4
    }
  }
}